Eltoukhy Helmy, Co-Chief Executive Officer of Guardant Health, Inc., has reported a series of stock transactions that took place at the end of September and the beginning of October 2026. This update is significant as it showcases the ongoing management activities within the company and highlights the importance of transparency in the corporate governance of publicly traded companies.
Background
Guardant Health, Inc. is a company focused on providing advanced genomic testing services, primarily in the medical laboratory sector. The company is incorporated in Delaware and operates under the Central Index Key (CIK) number 0001576280. Its fiscal year ends on December 31. The company is categorized under the SIC code for medical laboratories, indicating its involvement in the healthcare industry.
What the Filing Says
According to the recent SEC filing (accession number 0001752968-26-000018), Eltoukhy reported several transactions involving common stock. On September 30, 2026, he acquired 2,817 shares through a transaction coded as 'M' for acquisition. Following this transaction, he owned a total of 1,943,751 shares. Additionally, on October 1, 2026, he acquired 23,997 shares, bringing his total ownership to 1,966,320 shares. The filing also notes that he disposed of 1,428 shares at a price of $178.36 on the same day.
Impact
These transactions may affect various stakeholders, including shareholders and potential investors, as they reflect the management's confidence in the company's future. The reported acquisitions suggest a commitment to increasing ownership, which can be interpreted as a positive signal for the company's performance. Furthermore, the transparency demonstrated in these filings is crucial for maintaining investor trust.
What's Next
The filing does not say what happens next.